Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEA in Major Depression
NCT06063369Phase 2Unknown
- Sponsor
- Israeli Medical Center for Alzheimer's
- Start
- Dec 2022
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of palmitoylethanolamide in major depressive disorder (MDD), bipolar disorder (BD), sponsored by Israeli Medical Center for Alzheimer's. Status: unknown.
02
Drugs
palmitoylethanolamide
03
Conditions
major depressive disorder (MDD)bipolar disorder (BD)
Beyond the preview
Go deeper on NCT06063369.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06063369.